We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Target Molecule for Treatment of Multiple Sclerosis Identified

By LabMedica International staff writers
Posted on 01 Jun 2015
Print article
A protein marker expressed by a subset of human lymphocytes, which is capable of crossing the blood brain barrier and causing inflammation and damage to the neural tissues of individuals with multiple sclerosis (MS), has been singled out as a potential drug target for treatment of the disease.

Investigators at the University of Montreal (Canada) and their collaborators at the biotechnology company Prothena Corporation plc (Dublin, Ireland) have been studying MCAM (Melanoma Cell Adhesion Molecule), a 113,000-Dalton cell adhesion molecule.

They reported in the April 13, 2015, online edition of the journal Annals of Neurology that MCAM was expressed by human effector CD8+ T lymphocytes and was strikingly up-regulated during MS relapses. They demonstrated that MCAM+CD8+ T lymphocytes expressed more IL-17 (interleukin-17), IFN-gamma (interferon-gamma), GM-CSF (granulocyte-macrophage colony-stimulating factor) and TNF (tumor necrosis factor) than MCAM-negative lymphocytes, and exhibited an enhanced killing capacity towards oligodendrocytes. Blocking MCAM restricted the transmigration of CD8+ T lymphocytes across human blood-brain barrier endothelial cells in vitro. Blocking or depleting MCAM in vivo reduced chronic neurological damage in active, transfer, and spontaneous progressive animal MS models.

Research carried out by Prothena Corporation in the area of cell adhesion molecules has shown that MCAM functions like VELCRO hook-and-loop fasteners, allowing cells that express it to stick to the blood vessel wall and migrate into tissues to initiate their pathogenic process. For example, MCAM is expressed on pathogenic Th17-expressing immune cells that underlie inflammatory diseases and also is present on tumor cells involved in metastatic cancer. These insights have enabled the company to develop specific and novel antibodies that block MCAM’s VELCRO-like function and may have the ability to prevent disease-causing cells from spreading into tissue.

"We believe we have identified the first therapy that will impact the quality of life of people with multiple sclerosis by significantly reducing the disability and the disease's progression," said senior author Dr. Alexandre Prat, professor of neurosciences at the University of Montreal. "Our studies have shown that MCAM is necessary for the migration of CD4 and CD8 across the blood-brain barrier. If we block the interaction of MCAM with the protein to which it normally binds, we decrease the disease's activity. We observed a decrease of approximately 50% of the disease in mice with experimental autoimmune encephalomyelitis (EAE), the most widely used animal model of MS. What is especially significant is that we can stop the disease from the first symptoms in addition to having an impact on its progression, which is a first."

Related Links:
University of Montreal
Prothena Corporation plc


New
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Gold Member
ANA & ENA Screening Assays
ANA and ENA Assays
New
Flow Cytometer
BF – 710

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The bowel cancer breakthrough could result in better treatment outcomes (Photo courtesy of 123RF)

New RNA Molecules Can Help Predict Bowel Cancer Return Recurrence

Colorectal cancer accounts for 10% of all cancer-related deaths worldwide and was ranked as the second most common cause of cancer death in the United States in 2022. Currently, clinicians face diagnostic... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image

AI-Based Method Shows Promise for Pathological Diagnosis of Hereditary Kidney Diseases

Alport syndrome is a hereditary kidney disorder characterized by kidney dysfunction, sensorineural hearing loss, and ocular abnormalities. Early in the disease, patients experience hematuria, which is... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.